Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer

Hanna K. Sanoff, Dominic H. Moon, Dominic T. Moore, Jeremiah Boles, Courtney Bui, William Blackstock, Bert H. O'Neil, Somasundaram Subramaniam, Autumn J. McRee, Cheryl Carlson, Michael S. Lee, Joel E. Tepper, Andrew Z. Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

CRLX101 is a nanoparticle-drug conjugate with a camptothecin payload. We assessed the toxicity and pathologic complete response (pCR) rate of CRLX101 with standard neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer. A single-arm study was conducted with a 3 + 3 dose escalation phase Ib followed by phase II at the maximum tolerated dose (MTD). Thirty-two patients were enrolled with 29 (91%) patients having T3/4 and 26 (81%) N1/2 disease. In phase Ib, no patient experienced a dose limiting toxicity (DLT) with every other week dosing, while 1/9 patients experienced a DLT with weekly dosing. The weekly MTD was identified as 15 mg/m 2 . The most common grade 3–4 toxicity was lymphopenia, with only 1 grade 4 event. pCR was achieved in 6/32 (19%) patients overall and 2/6 (33%) patients at the weekly MTD. CRLX101 at 15 mg/m 2 weekly with neoadjuvant CRT is a feasible combination strategy with an excellent toxicity profile. Clinicaltrials.gov registration NCT02010567

Original languageEnglish (US)
Pages (from-to)189-195
Number of pages7
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume18
DOIs
StatePublished - Jun 2019
Externally publishedYes

Fingerprint

Camptothecin
Neoadjuvant Therapy
Radiotherapy
Rectal Neoplasms
Toxicity
Chemoradiotherapy
Maximum Tolerated Dose
Lymphopenia
Nanoparticles
IT-101
Capecitabine
Pharmaceutical Preparations

Keywords

  • Camptothecin
  • Maximum tolerated dose
  • Nanoparticle
  • Neoadjuvant
  • Pathologic complete response
  • Rectal cancer

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. / Sanoff, Hanna K.; Moon, Dominic H.; Moore, Dominic T.; Boles, Jeremiah; Bui, Courtney; Blackstock, William; O'Neil, Bert H.; Subramaniam, Somasundaram; McRee, Autumn J.; Carlson, Cheryl; Lee, Michael S.; Tepper, Joel E.; Wang, Andrew Z.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 18, 06.2019, p. 189-195.

Research output: Contribution to journalArticle

Sanoff, HK, Moon, DH, Moore, DT, Boles, J, Bui, C, Blackstock, W, O'Neil, BH, Subramaniam, S, McRee, AJ, Carlson, C, Lee, MS, Tepper, JE & Wang, AZ 2019, 'Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer', Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 18, pp. 189-195. https://doi.org/10.1016/j.nano.2019.02.021
Sanoff, Hanna K. ; Moon, Dominic H. ; Moore, Dominic T. ; Boles, Jeremiah ; Bui, Courtney ; Blackstock, William ; O'Neil, Bert H. ; Subramaniam, Somasundaram ; McRee, Autumn J. ; Carlson, Cheryl ; Lee, Michael S. ; Tepper, Joel E. ; Wang, Andrew Z. / Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2019 ; Vol. 18. pp. 189-195.
@article{c5868f2cc7ea48e6ab8797cc7d7b0a5e,
title = "Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer",
abstract = "CRLX101 is a nanoparticle-drug conjugate with a camptothecin payload. We assessed the toxicity and pathologic complete response (pCR) rate of CRLX101 with standard neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer. A single-arm study was conducted with a 3 + 3 dose escalation phase Ib followed by phase II at the maximum tolerated dose (MTD). Thirty-two patients were enrolled with 29 (91{\%}) patients having T3/4 and 26 (81{\%}) N1/2 disease. In phase Ib, no patient experienced a dose limiting toxicity (DLT) with every other week dosing, while 1/9 patients experienced a DLT with weekly dosing. The weekly MTD was identified as 15 mg/m 2 . The most common grade 3–4 toxicity was lymphopenia, with only 1 grade 4 event. pCR was achieved in 6/32 (19{\%}) patients overall and 2/6 (33{\%}) patients at the weekly MTD. CRLX101 at 15 mg/m 2 weekly with neoadjuvant CRT is a feasible combination strategy with an excellent toxicity profile. Clinicaltrials.gov registration NCT02010567",
keywords = "Camptothecin, Maximum tolerated dose, Nanoparticle, Neoadjuvant, Pathologic complete response, Rectal cancer",
author = "Sanoff, {Hanna K.} and Moon, {Dominic H.} and Moore, {Dominic T.} and Jeremiah Boles and Courtney Bui and William Blackstock and O'Neil, {Bert H.} and Somasundaram Subramaniam and McRee, {Autumn J.} and Cheryl Carlson and Lee, {Michael S.} and Tepper, {Joel E.} and Wang, {Andrew Z.}",
year = "2019",
month = "6",
doi = "10.1016/j.nano.2019.02.021",
language = "English (US)",
volume = "18",
pages = "189--195",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer

AU - Sanoff, Hanna K.

AU - Moon, Dominic H.

AU - Moore, Dominic T.

AU - Boles, Jeremiah

AU - Bui, Courtney

AU - Blackstock, William

AU - O'Neil, Bert H.

AU - Subramaniam, Somasundaram

AU - McRee, Autumn J.

AU - Carlson, Cheryl

AU - Lee, Michael S.

AU - Tepper, Joel E.

AU - Wang, Andrew Z.

PY - 2019/6

Y1 - 2019/6

N2 - CRLX101 is a nanoparticle-drug conjugate with a camptothecin payload. We assessed the toxicity and pathologic complete response (pCR) rate of CRLX101 with standard neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer. A single-arm study was conducted with a 3 + 3 dose escalation phase Ib followed by phase II at the maximum tolerated dose (MTD). Thirty-two patients were enrolled with 29 (91%) patients having T3/4 and 26 (81%) N1/2 disease. In phase Ib, no patient experienced a dose limiting toxicity (DLT) with every other week dosing, while 1/9 patients experienced a DLT with weekly dosing. The weekly MTD was identified as 15 mg/m 2 . The most common grade 3–4 toxicity was lymphopenia, with only 1 grade 4 event. pCR was achieved in 6/32 (19%) patients overall and 2/6 (33%) patients at the weekly MTD. CRLX101 at 15 mg/m 2 weekly with neoadjuvant CRT is a feasible combination strategy with an excellent toxicity profile. Clinicaltrials.gov registration NCT02010567

AB - CRLX101 is a nanoparticle-drug conjugate with a camptothecin payload. We assessed the toxicity and pathologic complete response (pCR) rate of CRLX101 with standard neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer. A single-arm study was conducted with a 3 + 3 dose escalation phase Ib followed by phase II at the maximum tolerated dose (MTD). Thirty-two patients were enrolled with 29 (91%) patients having T3/4 and 26 (81%) N1/2 disease. In phase Ib, no patient experienced a dose limiting toxicity (DLT) with every other week dosing, while 1/9 patients experienced a DLT with weekly dosing. The weekly MTD was identified as 15 mg/m 2 . The most common grade 3–4 toxicity was lymphopenia, with only 1 grade 4 event. pCR was achieved in 6/32 (19%) patients overall and 2/6 (33%) patients at the weekly MTD. CRLX101 at 15 mg/m 2 weekly with neoadjuvant CRT is a feasible combination strategy with an excellent toxicity profile. Clinicaltrials.gov registration NCT02010567

KW - Camptothecin

KW - Maximum tolerated dose

KW - Nanoparticle

KW - Neoadjuvant

KW - Pathologic complete response

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=85063972479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063972479&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2019.02.021

DO - 10.1016/j.nano.2019.02.021

M3 - Article

C2 - 30858085

AN - SCOPUS:85063972479

VL - 18

SP - 189

EP - 195

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

ER -